What people changed
What people changed.
Three people, anonymised. We changed the names and blurred the details to protect them. Everything else is real: the variants we found, what they mean, and the changes each person made to live a little differently afterwards.
With the explicit consent of each person for the publication of the abstracted account below.
01
What changed
He made three small changes, early, while they still compound. He added a yearly iron check (ferritin) to his bloodwork, a quiet habit that protects decades of training. He switched his B-complex to a methylated one. And he kept the pre-training espresso, now sure his body handles it. His analysis is a reference he returns to.
The person
An endurance athlete in his late thirties. No symptoms, training six days a week, wanting to look 'before something appears'.
What they asked
What his body is built for, how it handles medication, and the everyday levers: caffeine, alcohol, recovery. He skipped the inheritance area; he was not yet planning children.
What was found
- HFE, C282Y heterozygoteOne inherited copy of the most common iron-overload (haemochromatosis) variant. One copy alone does not cause iron overload. But together with being male and eating an iron-rich training diet, it makes a yearly iron blood test a sensible, low-cost habit for him.
- MTHFR, 677CT compoundHis body processes folate (a B vitamin) a little less efficiently. Not the alarming diagnosis it is sometimes made out to be; in his case, simply a reason to choose a methyl-folate supplement over plain folic acid if he takes one.
- CYP1A2, fast caffeine metaboliserHis body clears caffeine quickly, which fits the heavy pre-training coffee he described. For a fast metaboliser, timing the last cup of the day matters less than it would for someone who clears it slowly.
02
What changed
Two things changed for them. They stopped worrying about cystic fibrosis, the question they had asked first, carrying one less unknown into a pregnancy. And they noted to mention the Factor V finding to her OB at the booking visit, putting attention where it matters before it matters. The lineage they now talk about most; it has become part of how they think about the family they are starting.
The person
A couple in their early thirties, hoping for a child within two years. Both reasonably fit, with no family history they knew of.
What they asked
What they each carry, and what that could mean for a future child, read across both of them at once. They were not looking for clinical answers, just a plain-language picture before they started a family.
What was found
- CFTR, ΔF508 heterozygote (one of two)She carries one copy of the most common cystic fibrosis variant; he carries none. Because it takes two copies to cause the condition, a future child has roughly a one in two chance of being a healthy carrier and effectively no chance of being affected, based on the data we hold.
- Factor V Leiden, both heterozygousBoth partners carry one copy of a variant linked to blood clotting. No treatment is needed now. It is simply worth mentioning to her obstetrician at the first pregnancy visit, since pregnancy measurably raises clot risk in carriers.
- Mitochondrial, haplogroup K1aHer maternal line traces through Ashkenazi Jewish Europe and, earlier, across the Near East. Set alongside his paternal line (Y-haplogroup R1b-M269), these are the two ancestral lines a future child would carry forward.
03
What changed
He brought his analysis to his physician, and most of it was settled in one conversation. The statin was swapped for one that clears differently, and the muscle aches went away. The new PPI was started at the lower dose. The warfarin note now sits in his chart, useful years before anyone needs it.
The person
A man in his mid-fifties, on three regular medications including a statin that did not sit well with him. He was about to start a fourth.
What they asked
How his body handles medication, first and foremost. He wanted one document to bring to his physician that captured everything worth knowing before another prescription was added.
What was found
- SLCO1B1, reduced transporter functionThe liver protein that clears statins from the blood works at reduced capacity, so statins build up more. That fits the muscle aches he reported on simvastatin, and points to a statin that relies less on this pathway, at his physician's discretion.
- CYP2C19, intermediate metaboliserThe fourth medication being considered was a PPI (a common acid-reducing drug). He breaks it down more slowly than average, so it lingers a little longer. No reason to avoid it, just a reason to start at the lower dose and reassess.
- CYP2C9 + VKORC1, combined sensitivityIf the blood thinner warfarin is ever prescribed, this pair of variants predicts he would be unusually sensitive to standard doses. Nothing to do today; the note travels with him to any future conversation about blood thinners.
A note
None of the above is medical advice.
An analysis is informational and educational, not clinical. It is written to be considered and brought to a physician where the variants imply a clinical conversation. The outcomes above describe what these people chose to do after speaking with their own healthcare professionals. Your analysis, and your decisions, will be your own.
Your own analysis
Join the people who decided to age by design.
The accounts above sit next to each other not because their authors do, but because the same scientist sat with each one, and turned what was written in their DNA into a few choices worth living by. Your conversation would begin the same way.